These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 2355442)

  • 21. Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients.
    Kamb ML; Murphy JJ; Jones JL; Caston JC; Nederlof K; Horney LF; Swygert LA; Falk H; Kilbourne EM
    JAMA; 1992 Jan; 267(1):77-82. PubMed ID: 1727200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Eosinophilia-myalgia syndrome following administration of a L-tryptophan preparation].
    Frick P; Frey R
    Schweiz Med Wochenschr; 1990 Nov; 120(44):1633-5. PubMed ID: 2251478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical spectrum of eosinophilia-myalgia syndrome--California.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1990 Feb; 39(6):89-91. PubMed ID: 2105444
    [No Abstract]   [Full Text] [Related]  

  • 24. Eosinophilia-myalgia syndrome in patients ingesting a single source of L-tryptophan.
    Henning KJ; Jean-Baptiste E; Singh T; Hill RH; Friedman SM
    J Rheumatol; 1993 Feb; 20(2):273-8. PubMed ID: 8474064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eosinophilia-myalgia syndrome in Canada.
    Wilkins K; Wigle D
    Can Dis Wkly Rep; 1990 Feb; 16(6):28-30. PubMed ID: 2337932
    [No Abstract]   [Full Text] [Related]  

  • 26. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
    Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
    Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eosinophilia myalgia syndrome: cases in Canada.
    Wilkins K; Wigle D
    Can Dis Wkly Rep; 1989 Dec; 15(50):251-2. PubMed ID: 2611918
    [No Abstract]   [Full Text] [Related]  

  • 28. Tryptophan-induced eosinophilia-myalgia syndrome.
    Criswell LA; Sack KE
    West J Med; 1990 Sep; 153(3):269-74. PubMed ID: 2219890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cause and pathogenesis of the eosinophilia-myalgia syndrome.
    Varga J; Uitto J; Jimenez SA
    Ann Intern Med; 1992 Jan; 116(2):140-7. PubMed ID: 1727618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eosinophilia-myalgia syndrome: coming to grips with a new illness.
    Kilbourne EM
    Epidemiol Rev; 1992; 14():16-36. PubMed ID: 1289111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of L-tryptophan for the etiology of eosinophilia-myalgia syndrome.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1990 Aug; 39(34):589-91. PubMed ID: 2166897
    [No Abstract]   [Full Text] [Related]  

  • 32. Eosinophilia-myalgia syndrome and tryptophan production: a cautionary tale.
    Mayeno AN; Gleich GJ
    Trends Biotechnol; 1994 Sep; 12(9):346-52. PubMed ID: 7765187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From the Centers for Disease Control. Analysis of L-tryptophan for the etiology of eosinophilia-myalgia syndrome.
    JAMA; 1990 Oct; 264(13):1656. PubMed ID: 2169007
    [No Abstract]   [Full Text] [Related]  

  • 34. Eosinophilic fasciitis associated with tryptophan ingestion. A manifestation of eosinophilia-myalgia syndrome.
    Gordon ML; Lebwohl MG; Phelps RG; Cohen SR; Fleischmajer R
    Arch Dermatol; 1991 Feb; 127(2):217-20. PubMed ID: 1990986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case of L-tryptophan-induced eosinophilia-myalgia resulting in death.
    Marks DR
    Conn Med; 1990 Oct; 54(10):552-4. PubMed ID: 2265542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eosinophilic fasciitis is clinically distinguishable from the eosinophilia-myalgia syndrome and is not associated with L-tryptophan use.
    Varga J; Griffin R; Newman JH; Jimenez SA
    J Rheumatol; 1991 Feb; 18(2):259-63. PubMed ID: 2023221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York.
    Back EE; Henning KJ; Kallenbach LR; Brix KA; Gunn RA; Melius JM
    J Rheumatol; 1993 Apr; 20(4):666-72. PubMed ID: 8496862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of the eosinophilia-myalgia syndrome associated with use of an L-tryptophan product.
    Flannery MT; Wallach PM; Espinoza LR; Dohrenwend MP; Moscinski LC
    Ann Intern Med; 1990 Feb; 112(4):300-1. PubMed ID: 2297207
    [No Abstract]   [Full Text] [Related]  

  • 39. L-tryptophan-associated eosinophilic fasciitis prior to the 1989 eosinophilia-myalgia syndrome outbreak.
    Hibbs JR; Mittleman B; Hill P; Medsger TA
    Arthritis Rheum; 1992 Mar; 35(3):299-303. PubMed ID: 1536667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan.
    Hertzman PA; Blevins WL; Mayer J; Greenfield B; Ting M; Gleich GJ
    N Engl J Med; 1990 Mar; 322(13):869-73. PubMed ID: 2314421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.